In the first quarter, China´s foreign trade of raw materials and preparations grew significantly and made a good start
Release Time: 2018-10-10 09:37:26 Visited: 3479 times
A few days ago, China Chamber of Commerce for import and export of medical and health care products (hereinafter referred to as chamber of Commerce for medical insurance) released the data of drug import and export in the first quarter of 2017. Data show that in the first quarter, China's foreign trade of APIs and preparations grew significantly and made a good start. "It is predicted that the import and export of medicine this year will be better than last year." Xu Ming, vice president of the medical insurance chamber of Commerce, said.
The export situation of pharmaceutical preparations is improving
Affected by the cyclical impact of the world economy and the decline in the performance of multinational enterprises, China's pharmaceutical exports in 2016 decreased slightly by 0.24% year-on-year; while in the first quarter of 2017, China's pharmaceutical exports reached US $770 million, with a year-on-year growth of 10.9%, and the pharmaceutical exports stabilized with a good trend.
In terms of categories, in the first quarter of this year, the exports of traditional antibiotics, vitamins, hormones and insulin drugs in preparations all increased by a large margin. From the market point of view, China's pharmaceutical exports to South America and South Korea declined significantly, but to the European Union, the United States, ASEAN and other markets increased significantly, with a year-on-year growth rate of 71%, 25% and 15% respectively. From the perspective of enterprise performance, the forms of domestic pharmaceutical enterprises participating in international division of labor are diversified. LVYE, humanwell, Huahai and Fosun have successively acquired European and American Indian enterprises and expanded generic drug production lines. Hengrui, Zhengda Tianqing and Shiyao have authorized their products under research to multinational enterprises. The pace of R & D and international listing has been further accelerated. Taide, Huayao and other enterprises have also increased their exploration of the Japanese market intensity. According to this prediction, the chamber of health insurance predicts that the export of Chinese pharmaceutical products to developed countries is expected to accelerate in the future.
However, China's pharmaceutical export is still facing uncertainties. The U.S. abolishes Obama's health care reform, plans to reform the drug review and biomedicine field, brexit of the U.K., referendum of Italy, slow economic recovery of Europe, economic development of Japan and South Korea affected by politics, and payment capacity of emerging economies in Africa and South America affected by falling commodity prices and tightening financial conditions have all brought certain uncertainty to China's pharmaceutical export.
In contrast to the domestic situation, with the implementation of generic drug quality and efficacy consistency evaluation and "two vote system", the pharmaceutical industry will enter a new round of adjustment period, but the overall pharmaceutical market will still expand. Therefore, the chamber of health insurance predicts that China's import and export of Western medicine preparations will maintain a relatively stable growth in 2017, but the growth rate is difficult to increase significantly.
Steady growth of API foreign trade
In 2016, China's foreign trade volume of API was 33.273 billion US dollars, which was down by 33.273 billion US dollars. In the first quarter of 2017, with the overall recovery of China's foreign trade, API trade also showed a steady growth momentum, with the import and export volume reaching US $8.882 billion, a year-on-year increase of 9.6%.
In the first quarter, China's API export volume was US $6.722 billion, an increase of 6.71% over the same period last year. However, there was a situation of price reduction and promotion. While the export volume increased by 14.21%, the average export price decreased by 6.57%. Amino acids, penicillins, hormones, cephalosporins and other bulk APIs are still the main categories for price reduction and promotion. At the same time, the prices of some raw materials rose, the average export prices of antipyretic and analgesic drugs hit the bottom and rebounded, and the prices of vitamins continued to rise. From the perspective of market division, China's API exports to all continents showed a positive growth in the first quarter, with exports to the United States and South Korea increasing by more than 20% year on year. Compared with exports, China's import volume of API in the first quarter was US $2.16 billion, with a year-on-year growth of 19.69%, showing a trend of volume increase and price decrease. While the import volume increased by 25.49%, the average import price decreased by 4.62%.
According to the analysis of data from China Medical Insurance chamber of Commerce, the first quarter created a good start for the whole year's API trade, and it is expected that the second quarter will continue to maintain a positive growth. In 2017, China's API trade will pick up, the annual export scale will continue to maintain, and the import scale will pick up slightly